Total Payments
$80,791
2024 Payments
$8,782
Companies
77
Transactions
1,294
Medicare Patients
5,195
Medicare Billing
$411,501
Payment Breakdown by Category
Research$48,187 (59.6%)
Food & Beverage$18,275 (22.6%)
Consulting$8,398 (10.4%)
Travel$5,730 (7.1%)
Education$167.22 (0.2%)
Other$35.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48,187 | 19 | 59.6% |
| Food and Beverage | $18,275 | 1,244 | 22.6% |
| Consulting Fee | $8,398 | 5 | 10.4% |
| Travel and Lodging | $5,730 | 15 | 7.1% |
| Education | $167.22 | 10 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $35.00 | 1 | 0.0% |
Payments by Type
Research
$48,187
19 transactions
General
$32,604
1,275 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $49,205 | 23 | $0 (2024) |
| Novo Nordisk Inc | $5,211 | 118 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $4,322 | 46 | $0 (2022) |
| Chiesi USA, Inc. | $3,743 | 5 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,884 | 96 | $0 (2024) |
| Biohaven Pharmaceutical Holding Company Ltd. | $1,757 | 10 | $0 (2022) |
| ABBVIE INC. | $1,302 | 86 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,161 | 74 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,111 | 7 | $0 (2017) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,030 | 93 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,782 | 130 | Eli Lilly and Company ($6,094) |
| 2023 | $6,060 | 120 | Chiesi USA, Inc. ($3,743) |
| 2022 | $45,347 | 141 | Eli Lilly and Company ($39,856) |
| 2021 | $2,837 | 139 | Eli Lilly and Company ($779.39) |
| 2020 | $3,602 | 112 | Eli Lilly and Company ($2,073) |
| 2019 | $4,038 | 199 | Novo Nordisk Inc ($2,082) |
| 2018 | $2,593 | 224 | AstraZeneca Pharmaceuticals LP ($407.50) |
| 2017 | $7,533 | 229 | SANOFI-AVENTIS U.S. LLC ($3,954) |
All Payment Transactions
1,294 individual payment records from CMS Open Payments — Page 1 of 52
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | ASSURITY (Device) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $6.73 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: PAIN | ||||||
| 12/12/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: ADHD | ||||||
| 12/09/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Insomnia | ||||||
| 12/03/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $34.14 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Respiratory | ||||||
| 11/22/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Endocrinology | ||||||
| 11/19/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.88 | General |
| Category: Diabetes | ||||||
| 11/14/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $8.60 | General |
| Category: Cardiology | ||||||
| 11/14/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $8.56 | General |
| Category: Inflammation | ||||||
| 11/07/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Diabetes Care | ||||||
| 11/07/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: PAIN | ||||||
| 11/06/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Food and Beverage | Cash or cash equivalent | $14.72 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 10/17/2024 | PFIZER INC. | ABRYSVO (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: VACCINES | ||||||
| 10/14/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Diabetes Care | ||||||
| 10/09/2024 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: ADHD | ||||||
| 10/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: Cardiology | ||||||
| 10/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $8.05 | General |
| Category: Inflammation | ||||||
| 10/08/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: PAIN | ||||||
| 10/06/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: Diabetes | ||||||
| 10/03/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Diabetes Care | ||||||
| 10/03/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Oncology | ||||||
| 10/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $35,690 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $3,294 | 1 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $3,190 | 1 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $2,328 | 2 |
| Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type | SANOFI US SERVICES INC. | $1,111 | 7 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $889.86 | 2 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $836.34 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $411.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $402.14 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $34.19 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,316 | 2,077 | $411,920 | $110,746 |
| 2022 | 19 | 1,342 | 2,078 | $332,915 | $118,314 |
| 2021 | 16 | 1,347 | 2,198 | $265,337 | $106,769 |
| 2020 | 16 | 1,190 | 2,067 | $250,562 | $75,673 |
Total Patients
5,195
Total Services
8,420
Medicare Billing
$411,501
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 382 | 816 | $267,648 | $63,585 | 23.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 219 | 312 | $72,384 | $17,915 | 24.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 132 | 132 | $27,720 | $17,156 | 61.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 17 | 17 | $4,250 | $2,828 | 66.5% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 62 | 75 | $7,500 | $2,597 | 34.6% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 54 | 128 | $7,680 | $2,076 | 27.0% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 36 | 39 | $3,900 | $954.57 | 24.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 71 | 106 | $4,770 | $920.32 | 19.3% |
| 87880 | Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | Office | 2023 | 40 | 48 | $2,400 | $777.60 | 32.4% |
| 81003 | Automated urinalysis test | Office | 2023 | 185 | 263 | $5,260 | $574.52 | 10.9% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 60 | 79 | $4,424 | $572.90 | 12.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 36 | 38 | $1,710 | $340.67 | 19.9% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Office | 2023 | 11 | 11 | $1,650 | $250.08 | 15.2% |
| 69209 | Removal of impacted ear wax by washing | Office | 2023 | 11 | 13 | $624.00 | $198.08 | 31.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 429 | 905 | $222,398 | $72,401 | 32.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 196 | 250 | $45,184 | $15,290 | 33.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 111 | 111 | $18,930 | $14,463 | 76.4% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 26 | 26 | $4,610 | $4,154 | 90.1% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2022 | 64 | 74 | $7,400 | $3,112 | 42.1% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2022 | 39 | 80 | $4,246 | $1,302 | 30.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $3,754 | $1,258 | 33.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 69 | 127 | $4,950 | $1,208 | 24.4% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 38 | 41 | $4,118 | $971.71 | 23.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 13 | 13 | $1,050 | $891.02 | 84.9% |
| 81003 | Automated urinalysis test | Office | 2022 | 170 | 246 | $4,197 | $534.23 | 12.7% |
About Dr. John Gabriel, MD
Dr. John Gabriel, MD is a Family Medicine healthcare provider based in North Richland Hills, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2005. The National Provider Identifier (NPI) number assigned to this provider is 1407844764.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Gabriel, MD has received a total of $80,791 in payments from pharmaceutical and medical device companies, with $8,782 received in 2024. These payments were reported across 1,294 transactions from 77 companies. The most common payment nature is "" ($48,187).
As a Medicare-enrolled provider, Gabriel has provided services to 5,195 Medicare beneficiaries, totaling 8,420 services with total Medicare billing of $411,501. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location North Richland Hills, TX
- Active Since 10/11/2005
- Last Updated 08/15/2013
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1407844764
Products in Payments
- SOLIQUA (Drug) $3,902
- Rybelsus (Drug) $2,189
- NURTEC ODT (Drug) $2,032
- Victoza (Drug) $1,933
- TOUJEO (Drug) $1,288
- JARDIANCE (Drug) $939.47
- VRAYLAR (Drug) $780.13
- FARXIGA (Drug) $655.74
- TRELEGY ELLIPTA (Drug) $638.16
- SYMBICORT (Drug) $472.49
- Ozempic (Drug) $400.08
- JANUVIA (Drug) $356.61
- Vascepa (Drug) $340.64
- UBRELVY (Drug) $321.95
- MOUNJARO (Drug) $276.49
- BEVESPI AEROSPHERE (Drug) $270.89
- VESICARE (Drug) $266.34
- Azstarys (Drug) $250.76
- Trintellix (Drug) $244.34
- EMGALITY (Drug) $243.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in North Richland Hills
Dr. Joseph Lambert, Md, MD
Family Medicine — Payments: $15,166
Family Medicine $15,166
Afshin Ashrafian, Md, MD
Family Medicine — Payments: $9,607
Family Medicine $9,607
Dr. Elaine Paik, Md, MD
Family Medicine — Payments: $6,924
Family Medicine $6,924
Tehmina Tasneem, M.d, M.D
Family Medicine — Payments: $5,217
Family Medicine $5,217
Mark Hammonds, Md, MD
Family Medicine — Payments: $1,676
Family Medicine $1,676
Kenneth Archer, Md, MD
Family Medicine — Payments: $764.63
Family Medicine $764.63